RapidAI

RapidAI is a leader in deep clinical AI, operating an enterprise platform that provides real-time decision support to over 2,500 hospitals in more than 100 countries. Founded in 2012, the company has a strong foundation in clinical research, with its technology underpinning major trials and boasting 14 FDA-cleared modules. Its solutions focus on high-acuity areas like stroke and pulmonary embolism, aiming to streamline workflows, enhance diagnostic confidence, and improve financial performance for healthcare providers.

The Rapid Enterprise™ Platform is a comprehensive clinical AI system offering triage, localization, quantification, characterization, visualization, and longitudinal tracking for medical imaging. It integrates a mobile app for alerts and collaboration, analytics tools, and interoperability frameworks to support decision-making across neurovascular, cardiac/vascular, and radiology workflows.

RapidAI competes in the crowded AI diagnostics market against large players like GE HealthCare and Siemens Healthineers, as well as pure-play AI companies such as Viz.ai (in stroke) and Aidoc. Its competitive differentiation lies in its deep, clinically validated focus on specific high-acuity disease states, its enterprise platform approach, and its proven impact on clinical trials and guidelines.